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Context: Premature adrenarche (PA) is associated with childhood overweight and hyperinsulinemia;
the long-term cardiometabolic outcome is unknown.
Objective: To study cardiometabolic profile in adult women with previous PA.
Design and participants: Thirty women with PA and 41 control subjects were followed from pre-
puberty to young adulthood.
Main outcome measures: Prevalence of the metabolic syndrome (MetS) and clinical and biochemical
cardiovascular risk factors.
Results: There were no differences in the prevalence of MetS or in any parameters indicating dysli-
pidemia, hypertension, hepatosteatosis, atherosclerosis, or low-grade inflammation between the study
groups. However, prevalence of insulin resistance (IR; P 5 0.014) and acanthosis nigricans (P 5 0.010)
was higher in the PA group. Neither fasting glucose nor insulin concentrations differed between the
study groups, but HbA1c [adjusted for body mass index (BMI) P 5 0.011] and Homeostatic Model
Assessment of Insulin Resistance (P 5 0.044; BMI-adjusted P 5 nonsignificant) were higher in the PA
group. Although BMI and fat percentage were comparable between the study groups, the PA group had
higher central fat mass than the control group. In the whole study population, MetS and IR were
associated with greater adult fat mass, but no prepubertal factors predicting later IR were found.
Conclusion:PA does not seem to be associated withMetS, dyslipidemia, hypertension, atherosclerosis,
or low-grade inflammation in young adult women. However, some women with PA may be at an in-
creased risk of unfavorable glucose metabolism, which is associated with increased central adiposity at
adult age rather than determined by prepubertal factors.
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
Freeform/KeyWords: dehydroepiandrosterone sulfate, body composition, metabolic syndrome,
insulin resistance
Abbreviations: ALT, alanine aminotransferase; AN, acanthosis nigricans; BMI, body mass index; BP, blood pressure; DHEAS,
dehydroepiandrosterone sulfate; GT, glutamyl transferase; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic
model assessment for insulin resistance; hsCRP, high-sensitivity C-reactive protein; IR, insulin resistance; LDL-C, low-density
lipoprotein cholesterol; MetS, metabolic syndrome; OGTT, oral glucose tolerance test; PA, premature adrenarche; PP, premature
pubarche; TC, total cholesterol; TG, triglyceride; WC, waist circumference.
Received 23 May 2019
Accepted 9 July 2019
First Published Online 15 July 2019
ISSN 2472-1972
October 2019 | Vol. 3, Iss. 10






/jes/article-abstract/3/10/1771/5531556 by Viikki Science Library user on 12 N
ovem
ber 2019
Premature adrenarche (PA) refers to early maturation of the zona reticularis in the adrenal
cortex, which leads to an increase in the secretion of adrenal androgen precursors, mostly
dehydroepiandrosterone sulfate (DHEAS). When this is associated with clinical signs of
androgen action in a girl before the age of eight years, adrenarche is defined as premature
[1–3]. Androgenic signs of PA include adult-type body odor, comedones and acne, greasiness
of hair and skin, and pubic or axillary hair. The most studied PA phenotype including the
appearance of pubic hair is termed premature pubarche (PP) [1–3].
PA has been linked to unfavorable metabolic profile at prepubertal and early pubertal age:
Children with PA tend to have an increased prepubertal body mass index (BMI) [4–6] and
hyperinsulinemia [7–9]. Some studies have reported also an unfavorable lipid profile [7, 10]
or slightly increased blood pressure (BP) in prepubertal girls with PP [4]. A tendency to be
overweight and hyperinsulinemic seems to persist at least until early puberty [7, 11, 12], and
it has been suggested that PA is a risk factor for the development of later cardiometabolic
abnormalities, such as the metabolic syndrome (MetS) [13]. However, the number of studies
exploring long-term cardiovascular risk profile and adult outcomes of PA is limited.
In our prospective case-control study, we have followed a cohort of girls with PA from
prepuberty to young adult age [14–16]. At prepubertal age, these girls with PA had tall
stature, a tendency to be overweight and hyperinsulinemic, and an increased prevalence of
childhood MetS [14]. At pubertal age, BMI was higher in PA than control girls [15] and, at
young adult age, girls with PA still tended to have slightly higher median BMI and waist
circumference (WC) [16]. In the current study, our goal was to investigate whether these
adult women with a history of PA have a more unfavorable cardiometabolic risk factor profile
or body composition than healthy control subjects. Furthermore, if any cardiometabolic risk
factors were detected more frequently in women with PA, the secondary objective was to
analyze possible explanatory and predictive factors.
1. Subjects and Methods
A. Subjects and Design
The design of our case-control follow-up study has been described previously [16]. Altogether,
30 patients with PA and 42 healthy, age- and sex-matched control womenwere first examined
in prepuberty (median age, 7.6 years) and re-examined at young adult age (median age, 18.1
years). We did not find any differences in prepubertal data between the groups of PA females
when compared with the PA females who participated in a follow-up visit at age 18, to those
who did not. There were differences between the PA and control group in prepubertal data
as shown in Table 1. Women with PA had at least one clinical sign of adrenal androgen
action (i.e., adult-type body odor, greasiness of hair and skin, comedones/acne, and axillary or
pubic hair) together with increased DHEAS secretion before the age of 8 years, and other
sources of hyperandrogenism (including central puberty, congenital adrenal hyperplasia, and
androgen-producing tumors) had been excluded.
All control subjects were healthy, did not use any medications, and have any premature
signs of androgen action. Between the baseline and follow-up examinations, one woman in
the control group had been diagnosed with familial hypercholesterolemia and her data were
excluded from the analyses. None of the other women with PA or control women reported any
significant health issues or use of long-term medications that could have an impact on the
results. The study protocol was approved by the Research Ethics Committee of the Hospital
District of Northern Savo and informed consents were obtained in accordancewith the ethical
principles stated in the Declaration of Helsinki.
B. Clinical Assessment
The procedures for gathering the prepubertal and birth data have been reported [14]. Table 1
depicts birth and prepubertal data of the women participating in the current study. At the
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follow-up examination from which data were collected for this study, pubertal development
was evaluated by one physician (J.L.) using Tanner staging scales [17]. Body composition was
assessed in the morning after an overnight fast, and all anthropometric parameters were
measured by a single trained research nurse. Height was measured with a calibrated
Harpenden stadiometer (Holtain Ltd., Crymych, United Kingdom) and recorded to the
nearest 0.1 cm as the mean of three repeated measurements. Weight was measured with a
calibrated electronic scale and recorded to the nearest 0.1 kg. WC was measured after ex-
halation at mid distance between the bottom of the rib cage and the top of the iliac crest, and
hip circumference was measured horizontally to the floor at the widest part of the hip at the
level of the greater trochanter, both recorded to the nearest 0.1 cm. Wrist circumference was
measured from the dominant arm and recorded to the nearest 0.1 cm. BP was measured by
one physician (J.L.) using a standard sphygmomanometer from the left arm in sitting position
after a 30-minute rest in a chair and recorded as the average of three repeatedmeasurements.
Acanthosis nigricans (AN) was evaluated by one trained physician (J.L.) and recorded as
present or absent. Information about smoking habits was collected by direct interviews.
C. Body Composition
Parameters of body composition (body fat mass and percentage, android and gynoid fat mass,
bone mineral content and density, and lean and muscle mass) were assessed using a dual-
energy X-ray absorptiometry device (Lunar Prodigy Advance; GEMedical Systems, Madison,
WI). Fat percentage was expressed as percentage of total body mass. Android and gynoid fat
were expressed as percentage of total body fat, and fat distribution as android-to-gynoid ratio
(android fat divided by gynoid fat). Android region was defined as the area between the ribs
Table 1. Birth and Prepubertal Data of the PA and Control Groups in the Study
PA Group (n 5 30) Control Group (n 5 41) Pa,b
Birth data
Gestational age, wk 40.1 (29.0–42.3) 40.1 (29.1–42.1) 0.767
Birth length, cm 49.5 (38.0–56.0) 50.0 (38.5–54.0) 0.056
Birth length, SD score 20.17 (1.06) 0.24 (0.89) 0.074
Birth weight, g 3510 (1020–5460) 3550 (1190–4590) 0.158
Birth weight, SD score 20.31 (-2.12 to 3.85) 20.01 (-2.08 to 1.99) 0.081
SGA, yes 2 (7) 4 (10) 0.773
Preterm, yes 1 (3) 1 (2) 0.742
Prepubertal data
Age, y 7.6 (4.8–9.1) 7.4 (5.8–8.8) 0.780
Height, cm 130.5 (8.7) 124.8 (6.9) 0.003
Weight, kg 31.5 (16.7–50.5) 24.6 (16.5–48.4) ,0.001
BMI, kg/m2 17.1 (14.2–25.1) 15.9 (13.2–22.5) 0.018
BMI, SD score 0.79 (1.30) 0.05 (1.07) 0.012
Fat mass, kg 7.2 (1.6–17.6) 4.2 (2.0–16.4) 0.007
Fat, % 21.8 (9.7–38.2) 17.1 (9.2–33.4) 0.017
Lean mass, kg 24.3 (4.2) 21.7 (3.0) 0.008/0.341c
Muscle mass, kg 22.6 (4.1) 20.2 (2.8) 0.008/0.348c
Areal BMD LS, g/m2 0.72 (0.08) 0.67 (0.07) 0.019/0.197c
Areal BMD FN, g/m2 0.73 (0.09) 0.68 (0.10) 0.056/0.211c
Areal BMD F, g/m2 0.75 (0.10) 0.71 (0.08) 0.070/0.384c
Continuous variables are expressed as mean (SD) or median (range), and categorical variables as no. (%). Boldface
indicates statistical significance.
Abbreviations: BMD, bonemineral density; F; femur; FN, femoral neck; LS, lumbar spine; SGA, small for gestational
age.
aThe independent samples t test or the Mann-Whitney U test for continuous variables and Pearson x2 test for
categorical variables.
bStatistical significance set at P , 0.05.
cLean and muscle mass and BMDs were compared also with BMI adjustment ,using one-way analysis of covariance.
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and the pelvis that is totally enclosed by the trunk region. The gynoid region included the hips
and upper thighs, overlapping both the leg and trunk regions.
D. Carotid Artery Measurements
Ultrasound measurements were performed by trained sonographers following the standard-
ized protocol described previously [18]. With the woman in supine position, carotid artery
imaging was performed using Sequoia 512 ultrasound scanner (Acuson, Mountain View, CA)
equipped with a 14-MHz linear array transducer. The ECG signal (modified chest lead 5) was
recorded and presented along with B-mode image sets. A resolution box function was used to
scan the left common carotid artery to record a 25-mm 3 15-mm (width by height) image,
including the beginning of the carotid bifurcation and the distal common carotid artery. For
subsequent off-line analyses, a 5-second cine loop (25 frames per second) was digitally stored.
The derived parameters included intima media thickness and the inner artery diameters
during diastole and systole. The ability of the arteries to expand in response to the pulse
pressure caused by cardiac contraction and relaxation (i.e., carotid artery distensibility) was
calculated by dividing the relative change in diameter [(systolic diameter – diastolic diameter)/
diastolic diameter] by pulse pressure (systolic BP – diastolic BP). Systolic and diastolic BPs
used in this calculation were means of the measurements performed just before and imme-
diately after ultrasound scanning.
E. Biochemical Analyses
All blood sampleswere collected between 7:00 and 8:00 AM after an overnight fast. Serum samples
for high-sensitivityC-reactive protein (hsCRP)were stored at280°Cuntil assayed; other analyses
were performed immediately after sampling. Levels of total cholesterol (TC), high-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TGs)
were analyzed by a colorimetric enzymatic assay; insulin by an electrochemiluminescence im-
munoassay [19]; glucose by the hexokinase method; HbA1c by a turbidimetric inhibition im-
munoassay; alanine aminotransferase (ALT) andglutamyl transferase (GT) by thekineticmethod
(37°C) according to the International Federation of Clinical Chemistry; and hsCRP by a particle-
enhanced turbidimetric assay. The analyzers in these assays were either the Cobas 6000 c501 (to
measure TC, TG, ALT, GT, glucose, HbA1c, and hsCRP levels) or Cobas 6000 e601 (to measure
insulin, HDL-C, and LDL-C levels), both from Hitachi High Technology Co. (Tokyo, Japan). All
reagents were from Roche Diagnostics (Mannheim, Germany).
F. Definitions and Computed Indices
The definitions of MetS and its components (Table 2) were based on the definitions by Adult
Treatment Panel of the US National Cholesterol Education Project, International Diabetes
Federation, and World Health Organization [20, 21]. BMI was calculated as weight in ki-
lograms divided by the square of height in meters. Overall adiposity was classified using the
World Health Organization definitions for overweight and obesity, with BMI thresholds of 25
and 30 kg/m2, respectively. All anthropometric SD scores were calculated using the current
Finnish references [22, 23]. MetS score was derived by standardizing and then summing the
following continuously distributed variables: WC, mean BP [(systolic BP 1 diastolic BP)/2],
fasting insulin, fasting glucose, and the TG-to-HDL-C ratio [24]. Standardization of each
factor was based on the values of the control group and performed by subtracting the sample
mean from the individual mean and then dividing by sample SD.
Homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as
[fasting glucose (mg/dL) 3 fasting insulin (mU/L)]/405, and fasting glucose-to-insulin ratio
was calculated as fasting glucose (mg/dL) divided by fasting insulin (mU/L). According to the
97th percentile range reported from a cohort of young white women [25], HOMA-IR cutoff
level for insulin resistance (IR) was defined as 2.94. Hyperglycemia was defined as fasting
glucose concentration.100 mg/dL, impaired fasting glucose as fasting glucose concentration
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within the range of 110 to 126 mg/dL, and very high fasting glucose indicating diabetes
mellitus as fasting glucose concentration .126 mg/dL.
Hypertriglyceridemia was defined as fasting TG levels .150 mg/dL and low or very low
HDL-C as fasting HDL-C concentrations ,50 or 39 mg/dL, respectively. Dyslipidemia was
defined either by lipid subfractions (TG level. 150 mg/dL or HDL-C level, 50 mg/dL), or by
calculated TC-to-HDL-C ratio (.5.0) [26, 27].
G. Statistical Analyses
All statistical analyses were performed using SPSS 24.0 software (IBM Corp., Armonk, NY),
and the associations or statistical differences forwhichP, 0.05were considered significant. All
continuous variables were tested for normality with the Shapiro-Wilk test. Normally and non-
normally distributed continuous variables are expressed as mean (SD) or median (range),
respectively. The independent samples t test or theMann-WhitneyU testwere used to compare
the difference in continuous variables between the study groups (normal and non-normal
distribution, respectively). Several comparisons were also reanalyzed with BMI adjustment
using the one-way analysis of covariance (after logarithmic transformation in case of non-
normally distributed variables). In case of categorical variables, values are expressed as no. (%)
and the Pearson x2 or the Fisher exact test were used to analyze the differences between the
study groups. To analyze prepubertal risk factors for IR or higher HOMA-IR at adult age, we
used logistic or linear regression models, respectively. The covariates in these models were
standardized parameters of birth size; prepubertal BMI, height, and fat percentage; and
prepubertal serum DHEAS, androstenedione, IGF-1, and insulin concentrations.
2. Results
Women with PA and those in the control group had been bornmostly at term and appropriate
for gestational age without significant differences in the birth measures between the study
Table 2. Definitions of the MetS Used in the Current Study, Based on Criteria of the US National
Cholesterol Education Program ATP III [20], IDF[20], and WHO [21]
Definition Risk Factor Defining Level
ATP III Any three of the risk
factors in column 3
Central obesity WC $ 88 cm
Hyperglycemia Fasting glucose $ 100 mg/dL; or Rx
Dyslipidemia TG $ 150 mg/dL; or Rx
Dyslipidemia (separate
criteria)
HDL-C , 50 mg/dL; or Rx
Hypertension Systolic BP. 130 mmHg; or diastolic BP.85; or Rx
IDF Central obesity, plus
any two of the risk
factors in column 3
Central obesity (required) WC $ 80 cma
Hyperglycemia Fasting glucose $ 100 mg/dL
Hypertriglyceridemia TG $ 150 mg/dL; or Rx
Low HDL-C HDL-C , 50 mg/dL; or Rx
Hypertension Systolic BP. 130mmHg; or diastolic BP. 85; or Rx
WHO IR, plus any two of
the risk factors in
column 3
IR HOMA-IR . 2.94b
Obesity Waist-to-hip ratio . 0.85; or BMI . 30 kg/m2
Hypertriglyceridemia TG $ 150 mg/dL
Very low HDL-C HDL-C , 39 mg/dL
Hypertension BP . 140/90 mm Hg
(Microalbuminuria)c
Abbreviations: ATP III, Adult Treatment Panel III; IDF, International Diabetes Federation; Rx, pharmacological
treatment; WHO, World Health Organization.
aIDF defines central obesity by WC with cutoff levels that are specific for each population, the given value is for
European women.
bIR was defined by HOMA-IR with a cutoff level of 2.94, which is the previously reported 97th percentile for 17-y-old
white girls [23].
cWHO definition for MetS includes microalbuminuria, which was not analyzed in the current study.
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groups (Table 1). At the current follow-up examination, all women were postpubertal and at
least 3 years postmenarche. Tables 3–5 depict the essential findings of the women with PA
and control subjects in early adulthood.
A. MetS and Its Components
With at least one of the used definitions, three women with PA (10%) and two control subjects
(5%) could be defined as having MetS, and there was no significant difference between the
study groups in the prevalence ofMetS by any definition (Table 3). All womenwithMetSwere
either obese or significantly overweight (BMI. 28 kg/m2). The prevalence of IR was higher in
the women with PA than in control subjects (P5 0.014), and most of the women with PA with
IR (62%) were either overweight or obese. Except for IR, we did not detect any other sig-
nificant differences in the prevalence of MetS components between the study groups.
However, it should be noted that despite statistical insignificance, fasting hyperglycemia and
obesity were three to four times more common in the PA group than in control subjects
(Table 3).
The mean MetS score (including indexes for central obesity, hyperglycemia, hyper-
insulinemia, hypertension, and dyslipidemia) was higher in the PA group than in the control
group (P 5 0.026; Table 4). Each single index score defining the overall MetS score was
comparable between the study groups (P . 0.050); the higher overall MetS score in the PA
group was mostly explained by tendencies toward higher scores in the indexes of central
obesity and hyperinsulinism.
Table 3. Prevalence of theMetS and Its Components in the PA andControl Groups ofWomen ofMedian
Age, 18.1 Years
PA Group (n 5 30) Control Group (n 5 41) Pa,b
MetS
ATP III 3 (10) 1 (2) 0.190
IDF 3 (10) 1 (2) 0.190
WHO 2 (7) 2 (5) 0.828
MetS components
Overweight or obesity (BMI . 25 kg/m2) 12 (40) 9 (22) 0.100
Obesity (BMI . 30 kg/m2) 6 (20) 2 (5) 0.063
WC . 80 cm 11 (37) 10 (24) 0.263
WC . 88 cm 10 (33) 5 (12) 0.027
Waist-to-hip ratio .0.85 or BMI .30 kg/m2 10 (33) 10 (24) 0.408
Hyperglycemia (fP-glucose . 100 mg/dL) 7 (23) 3 (7) 0.090
IFG (fP-glucose, 110–126 mg/dL) 0 (0) 0 (0) 1
DM (fP-glucose $ 126) 1 (3) 0 (0) 0.435
IR (HOMA-IR . 2.94)c 13 (43) 6 (15) 0.014
Hypertriglyceridemia (fP-TG . 150 mg/dL) 1 (3) 2 (5) 0.717
Low HDLc (fP-HDL-C , 50 mg/dL) 5 (17) 3 (7) 0.281
Very low HDLc (fP-HDL-C , 39 mg/dL) 1 (3) 0 (0) 0.435
Ratio of TC to HDL-C .5.0 0 (0) 0 (0) 1
Dyslipidemiad 6 (20) 4 (10) 0.254
Systolic BP . 130 mm Hg 6 (20) 4 (10) 0.304
Diastolic BP . 85 mm Hg 5 (17) 2 (5) 0.125
BP . 140/90 mm Hg 2 (7) 0 (0) 0.175
Values are expressed as no. (%).
Abbreviations: ATP, Adult Treatment Panel; DM, diabetes mellitus; fP, fasting plasma; fS, fasting serum; IDF,
International Diabetes Federation; IFG, impaired fasting glucose; WHO, World Health Organization.
aStatistical differences between the study groups were analyzed using either the Pearson x2 test or the Fisher exact
test.
bStatistical significance was set at P , 0.05.
cIR was defined by HOMA-IR with a cutoff level of 2.94.
dDefined as hypertriglyceridemia, low HDL-C, or ratio of TC to HDL-C .5.0.










Among the biochemical parameters of glucose metabolism, both fasting glucose and insulin
levels (with and without BMI adjustment) were comparable between the study groups. Mean
HbA1c was slightly higher in the PA group than in control subjects and the difference
remained significant after adjustment for BMI (Table 4).
Among the calculated indicators of insulin sensitivity, fasting glucose-to-insulin ratio did
not differ significantly between the study groups, but HOMA-IR was higher in the PA group
than in control subjects (P 5 0.044; Table 4). However, the difference in HOMA-IR between
the study groups disappeared when adjusted for BMI. ANwas present in five women with PA
and none of the control subjects (P5 0.010; Table 4). Three of the women with ANwere obese
at prepubertal age and either overweight or obese at current examination, one had normal
weight at prepubertal age but was now overweight, and one was obese at prepubertal age but
had currently normal weight. Four of the five women with PA with AN manifested IR, and
each of the four was either overweight or obese at current examination. In regression an-
alyses including the whole cohort, we did not find any significant prepubertal determinants
for the presence of IR or higher HOMA-IR at adult age (data not shown).
C. Lipids, BP, Inflammation, Liver Function, and Smoking
There were no significant differences in serum hsCRP concentrations; in plasma ALT, GT,
TC, TG, HDL-C, and LDL-C concentrations; or in the TC-to-HDL-C ratio between the PA
group and control group (Table 4). Neither did systolic, diastolic, or mean BP differ signif-
icantly between the study groups. There was no significant difference in the number of
smokers between the study groups (Table 4).
D. Carotid Artery Ultrasound Measures
We did not detect any significant differences in the carotid artery ultrasound measurements
between the groups; intima media thickness, systolic and diastolic artery diameters, and
changes in artery diameters from diastole to systole were all similar in the women with PA
and control subjects (Table 4).
E. Body Composition
When compared with the control group, the women with PA had a trend toward higher adult BMI
and WC. Body fat percentages were comparable between the study groups (Table 4), but fat
distribution was more central in the PA group than in control subjects—more women with PA
than control subjects had WC .88 cm (Table 3) and the women with PA had higher android fat
percentage and android-to-gynoid ratio of the body fatmass than thewomen in the control group did
(Table 4). Adult lean and muscle mass, and total body bone mineral content and bone mineral
density were all significantly higher in the women with PA than in the control group, also after
adjustment for BMI (Table 4). Hip and wrist measures were comparable between the study groups.
In contrast to what was measured at adult age, the women with PA had significantly higher
prepubertal BMI SD score and fat percentage than the control group did, but BMI-adjusted pre-
pubertal lean and muscle mass, and areal BMDs were comparable between the study groups
(Table 1).
F. Comparison of the Women With PA With and Without IR
The women with PA with IR had significantly higher current BMI, WC, waist-to-height ratio,
and fat percentage than those without IR. The prevalence of overweight or obesity at
postpubertal examination was also nearly threefold in the women with PA with IR compared
with those without IR (P5 0.035; Table 5). Gestational age, birth size, prepubertal height and
BMI SD score, or fat percentage did not differ between the women with PA with and without
IR, and PP was equally common in both subgroups (Table 5).










In this study, we investigated the long-term cardiometabolic outcome of PA by following
previously formed cohorts of women with PA and control subjects from prepuberty to young
adulthood. The prevalence of adulthood MetS was low and similar in women with PA and
Table 4. Characteristics and Cardiovascular Risk Factors of the PA and Control Groups at Young
Adult Age
PA Group (n 5 30) Control Group (n 5 41) Pa,b
Age, y 18.1 (16.5–23.5) 18.1 (16.9–19.8) 0.950
MetS scorec 1.99 (4.18) 20.04 (3.04) 0.026
Smoking, yes 4 (13) 7 (17) 0.655
Anthropometryd
Height, cm 167.2 (6.8) 164.6 (5.1) 0.072
Weight, kg 63.3 (47.4–115.0) 59.8 (47.5–88.4) 0.011
BMI, kg/m2 22.8 (18.4–42.2) 21.6 (18.5–32.5) 0.068
BMI, SD score 0.94 (-0.92–3.41) 0.35 (-0.91–2.47) 0.068
WC, cm 75.5 (64.5–108.7) 71.9 (53.0–92.0) 0.059
Hip circumference, cm 94.1 (82.5–124.0) 92.0 (80.8–108.2) 0.082
Waist-to-height ratio 0.46 (0.38–0.66) 0.44 (0.33–0.55) 0.205
Waist-to-hip ratio 0.81 (0.71–0.90) 0.79 (0.62–0.93) 0.249
Hip-to-height ratio 0.56 (0.50–0.75) 0.55 (0.50–0.68) 0.269
Wrist circumference, cm 14.5 (13.5–16.9) 14.3 (13.3–15.8) 0.059
Wrist-to-height, % 8.8 (8.2–10.1) 8.7 (8.0–10.0) 0.503
Body composition (DXA)
Fat mass, kg 21.2 (11.7–55.5) 18.6 (5.8–42.7) 0.056
Fat, % 34.6 (23.2–53.6) 31.6 (11.4–49.3) 0.132
Android fat, % 7.7 (1.4) 6.8 (1.6) 0.015
Gynoid fat, % 21.2 (2.8) 22.3 (3.3) 0.156
Fat distribution, android-to-gynoid fat ratio 0.37 (0.11) 0.31 (0.10) 0.017
Lean mass, kg 43.8 (6.1) 40.2 (3.3) 0.004/0.031e
Muscle mass, kg 41.1 (5.8) 37.7 (3.1) 0.005/0.039e
BMC, total body excluding the head, kg 2.7 (0.4) 2.4 (0.3) 0.002/0.025e
BMD, total body excluding the head, g/cm2 1.18 (0.06) 1.12 (0.07) ,0.001/0.005e
BMD, total body excluding the head,
SD score
0.74 (0.77) 0.00 (0.97) 0.001/0.008e
BP
Systolic BP, mmHg 121 (15) 115 (11) 0.071/0.378e
Diastolic BP, mmHg 74 (9) 71 (7) 0.120/0.820e
Mean BP, mmHg 96 (10) 93 (7) 0.121/0.516e
Heart rate, beats/min 81 (11) 78 (9) 0.269/0.279e
Lipid profile
fP-TC, mg/dL 158 (120–220) 154 (100–274) 0.937/0.538e
fP-TG, mg/dL 72 (35–156) 65 (30–220) 0.590/0.634e
fP-HDL-C, mg/dL 62 (38–112) 65 (44–95) 0.561/0.785e
fP-LDL-C, mg/dL 81 (42–143) 85 (39–197) 0.827/0.450e
Ratio of TC to HDL-C 2.5 (1.5–4.3) 2.5 (1.8–4.5) 0.561/0.867e
Glucose metabolism
fP-glucose, mg/dL 94 (85–130) 92 (81–110) 0.205/0.195e
fWB-HbA1c, mmol/mol 34 (2) 32 (2) 0.004/0.011e
fS-insulin, mU/L 11 (4–56) 10 (2–24) 0.060/0.191e
FGIRf 8.8 (2.3–23.9) 9.6 (4.1–40.1) 0.059/0.223e
HOMA-IRg 2.6 (0.9–17.9) 2.1 (0.5–6.0) 0.044/0.172e
AN, yes 5 (17) 0 (0) 0.010
Carotid artery measurementsh
IMT, mm 0.47 (0.05) 0.48 (0.05) 0.734/0.521e
Systolic diameter, mm 5.85 (0.38) 5.75 (0.31) 0.228/0.529e
Diastolic diameter, mm 5.11 (0.36) 5.03 (0.32) 0.334/0.863e
Distensibility, %/mmHgi 0.286 (0.07) 0.290 (0.06) 0.790/0.858e
(Continued)
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control subjects. We found no significant differences between the study groups in the in-
dicators of dyslipidemia, hypertension, hepatosteatosis, atherosclerosis, or low-grade in-
flammation. However, the women with PA hadmore unfavorable fat distribution and glucose
metabolism than the control subjects did, and they also had a higher calculated mean MetS
score, based on their trend to higherWC and fasting insulin levels. Regarding themeasures of
glucose metabolism, the women with PA had higher HbA1c concentrations, HOMA-IR, and
prevalence of IR than did the control group. The observed abnormalities of glucose meta-
bolism were associated with current central adiposity.
Cardiometabolic risk can be deduced largely from the sum of the components of MetS, and
the findings in our study suggest PA does not associate with MetS at young adult age. To our
knowledge, there are no previous reports on the prevalence of adulthood MetS after PA. In
one study of prepubertal children, the prevalence of childhoodMetS was low in those with PA
and did not differ from that of control subjects [28]. In our cohort, the prevalence of childhood
MetS was higher in prepubertal girls with PA than control girls [14], whereas the prevalence
of adulthood MetS was relatively low in women with PA and did not differ from that of the
control group. In the study by Williams et al. [28], childhood MetS was seen only in obese
children, whether they had PA or not, and body adiposity was associated with the number of
MetS risk factors. Similarly, childhood MetS in our cohort was mostly explained by a higher
prevalence of obesity and hyperinsulinemia in girls with PA [14], and adulthood MetS was
detectable only in those women who were either overweight or obese.
Hyperinsulinemia is a common finding among prepubertal children with PA [8, 9, 14] and the
risk of decreased insulin sensitivity seems to be increased in girls with PA also at adolescence [7,
12]. In a study investigating Turkish girls with PP, decreased insulin sensitivity at pubertal age
could be predictedmostly by prepubertal BMI [12]. Our current study findings indicate the risk of
abnormalities in glucose metabolism persists to adult age and that the risk is strongly associated
with central adiposity. On the basis of their findings from oral glucose tolerance tests (OGTT),
Table 4. Characteristics andCardiovascular Risk Factors of the PA andControl Groups at YoungAdult
Age (Continued)
PA Group (n 5 30) Control Group (n 5 41) Pa,b
Liver function and inflammation
fP-ALT, U/L 17 (8–50) 16 (5–91) 0.486/0.921e
fP-GT, U/L 11 (7–27) 12 (4–43) 0.689/0.393e
fS-hsCRP, mg/L 0.7 (0.2–8.6) 0.6 (0.2–10.4) 0.225/0.664e
Continuous variables are expressed as mean (SD) or median (range), and categorical variables as no. (%).
Abbreviations: ALT, alanine aminotransferase; AN, acanthosis nigricans; BMC, bone mineral content; BMD, bone
mineral density; BMI, body mass index; BP, blood pressure; DXA, dual-energy X-ray absorptiometry; FGIR, fasting
glucose-to-insulin ratio; fWB, fasting whole blood; fP, fasting plasma; fS, fasting serum; GT, glutamyl transferase;
HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment for
insulin resistance; hsCRP, high-sensitive c-reactive protein; IMT, intima media thickness; LDL-C, low-density li-
poprotein cholesterol; MetS, metabolic syndrome score; PA, premature adrenarche; TC, total cholesterol; TG,
triglycerides.
aThe independent samples t test orMann-WhitneyU test were for continuous variables, and the Pearson x2 or Fisher
exact test for categorical variables.
bStatistical significance was set at P , 0.05.
cComprises the standardized and summed value of WC, levels of fasting glucose and fasting insulin, mean BP, and
ratio of TG to HDL-C [23].
dFrom other aspects than in the current study, height, weight, BMI, waist, and hip measures were reported pre-
viously in Liimatta et al. [16].
eSecond P value is from reanalysis of data with BMI adjustment using one-way analysis of covariance (after log-
arithmic transformation in the case of non-normally distributed variables).
fFasting glucose (mg/dL) divided by fasting insulin (mU/L).
gCalculated as [fasting glucose (mg/dL) 3 fasting insulin (mU/L)]/405.
hMeasured from left carotid artery by ultrasound with subject in lying supine.
iCalculated as [(systolic diameter – diastolic diameter)/diastolic diameter]/(sBP – dBP).
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Ibáñez et al. [29] have reported similar findings among Catalan girls with PP. Although the girls
were mostly lean, they had increased central fat mass, which was associated with hyper-
insulinemia [29]. In contrast, in a study byMeas et al. [30] in which 17-year-old French girls with
PP and control subjects whose BMI values were within the normal range completed OGTTs,
glucose tolerance was normal in all subjects without significant differences in plasma glucose or
serum insulin profiles between the study groups. Our results are not straightforwardly in line
with the findings ofMeas et al. [30], but discrepancies may be explained by possible differences in
body fat percentage and/or fat distribution between our cohort and that in the French study.
The associations between PA and dyslipidemia or hypertension are controversial. Some
studies have reported that PA is linked to abnormalities in lipid profile [4, 7, 10] or BP [4, 10], but
there also are reports suggesting normal lipid profile [30, 31] and BP [7] exist. In one of these
studies, Catalan girls with a history of PP had unfavorable lipid profile but normal systolic and
diastolicBP throughout their pubertal development [7]. In contrast, 27French girlswith ahistory
of PP had normal lipid profile at postpubertal age [30]. The results of our case-control follow-up
study suggest PA does not lead to increased risk of adulthood dyslipidemia or hypertension.
Previous studies have suggested that children with PA may be more susceptible to low-grade
inflammation and developing atherosclerosis, because they had increased circulating cytokine
levels [10, 32]. As far as we know, there are no studies measuring cardiovascular changes or
inflammation markers in PA at adult age. Although we previously found an association between
PA and circulating TNF-a in our prepubertal cohort [33], the adult women with PA and control
subjects in the current study had comparable serum hsCRP concentrations and carotid artery
measurements. Thus, our findings do not support the suggestion that PA is associated with long-
term, low-grade inflammation or atherosclerotic pathology. Cardiovascular risk could be evaluated
Table 5. Pre- and Postpubertal Characteristics of Women With PA With and Without IR at
Postpubertal Examination
Women With PA With
IRa (n 5 13)
Women With PA Without
IR (n 5 17) Pb,c
At birth
Gestational age, wk 40.0 (29.0 to 42.0) 40.1 (35.4 to 42.3) 0.760
Birth length, SD score 20.15 (1.33) 20.19 (0.85) 0.925
Birth weight, SD score 0.00 (1.82) 20.30 (0.75) 0.621
At prepubertal examination
(median age, 7.6 y)
Height, SD score 0.99 (1.17) 0.86 (0.85) 0.733
BMI, SD score 1.15 (1.29) 0.51 (1.28) 0.190
Fat, % 24.2 (9.8) 23.5 (10.1) 0.862
Lean mass, kg 24.5 (4.7) 24.0 (4.0) 0.788
Pubarche, yes 7 (54) 9 (53) 0.961
At postpubertal examination
(median age, 18.1 y)
Height, cm 167.3 (7.4) 167.1 (6.4) 0.944
BMI, kg/m2 25.1 (20.0–42.2) 22.2 (18.4–35.8) 0.039
BMI, SD score 1.46 (1.13) 0.54 (1.04) 0.028
WC, cm 88.4 (67.8–108.7) 73.8 (64.5–96.8) 0.031
Waist-to-height ratio 0.49 (0.40–0.66) 0.44 (0.38–0.61) 0.022
Waist-to-hip ratio 0.84 (0.74–0.90) 0.80 (0.71–0.89) 0.094
Fat, % 38.0 (27.0–50.1) 31.6 (23.2–53.6) 0.039
Lean mass, kg 45.1 (6.0) 42.3 (4.5) 0.165
Overweight or obesity, yesd 8 (62) 4 (24) 0.035
Continuous variables are expressed as mean (SD) or median (range), and categorical variables as no. (%).
aIR was defined by HOMA-IR with a cutoff level of 2.94.
bIndependent samples t test or theMann-WhitneyU test for continuous variables, and Pearson x2 test for categorical
variables.
cStatistical significance was set at P , 0.05.
dBMI . 25 kg/m2.
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alsowith calculatedMetS score [24] and, interestingly, thewomenwithPA in our studyhadhigher
MetS scores than the control group did. This difference wasmostly explained by the differences in
the indexes of central obesity and hyperinsulinism, and agreed well with our findings that PAwas
associated with increased central fat mass and IR but not with dyslipidemia or hypertension.
Although BMI, waist measures, and fat percentage did not differ significantly between our
study groups, thewomenwith PA hadmore centrally located fat. This finding is in accordance
with the findings from a Catalan cohort of girls with PP who were mostly lean but had
increased central fat mass throughout their pubertal development [29]. On the other hand,
our study findings suggest total body adiposity in women with PA tends to reduce and body
composition alters toward nonfat mass by adulthood. This finding is supported by some
previous studies. A Brazilian study following a group of girls with PP until different stages of
puberty reported that BMI and the prevalence of overweight and obesity tended to decrease
through time [11]. Also, in some other studies, BMI was reported to be increased in subjects
with PA in early puberty but normal at late- or postpubertal age [30, 34, 35].
It is well known that childhood obesity increases the risk of adulthood obesity [36], and
that obesity, especially central obesity, is associated with the development of IR [37].
Children with PA tend to be overweight at prepubertal and pubertal age [4–6], including the
girls with PA in our cohort [14, 15], so it is not surprising that central fat mass and the
prevalence of IR were higher in our PA group than in control subjects. We have speculated
that PA could be a part of an adaptive process in which the body tries to turn energy excess in
an anabolic direction by advancing the initiation and tempo of both adrenal and pubertal
maturation [16]. Also, because adrenal androgens may have antiatherogenic effects [38],
prolonged adrenal androgen excess in PA could be protective regarding cardiovascular risk.
However, if an energy-rich diet and a lifestyle that maintains obesity continue through
adolescence, this mechanism may not be enough at the individual level to prevent the
metabolic disadvantages associated with adiposity. Our current results support the as-
sumption that the metabolic risk in PA is driven by the presence of increased central adi-
posity, leading especially to the risk of abnormalities in glucose metabolism.
The major strength of our study is its prospective design investigating long-term metabolic
outcome of PA in young women with a carefully matched control group. We used common
definitions of MetS and studied a variety of known cardiovascular risk factors at defined age in
young adulthood. The limitations include a high drop-out rate and a relatively small sample
size at adult age, reducing the statistical power of the study. We did not perform postpubertal
OGTTs, which could have given more precise information about glucose metabolism and IR.
Because PA is suggested to be associated with ovarian hyperandrogenism [13], it should be
noted that we did not analyze the features related to polycystic ovarian syndrome in this study.
In conclusion, our study findings suggest that some women with PA may be at risk for
having decreased insulin sensitivity at young adult age. Maintaining or gaining increased
central adiposity by adulthood seems to be a major independent determinant for this risk,
rather than PA or other prepubertal factors related to PA. PA does not seem to be associated
with MetS, dyslipidemia, hypertension, atherosclerosis, or low-grade inflammation in young
adult females. Our results emphasize the importance of lifestyle interventions for childhood
overweight and obesity among girls with PA.
Acknowledgments
We thankAnneli Paloranta, Leila Antikainen, Katriina Simonen, and SannaKoponen for their valuable
contributions in clinical phase of this follow-up study.
Financial Support: This work was supported by Kuopio University Hospital (Kuopio, Finland),
the Foundation for Pediatric Research (Helsinki, Finland; J.L.), the Finnish Medical Foundation
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IGF-1 concentrations in girls with a history of premature adrenarche: attenuation of the phenotype by
adulthood. Front Endocrinol (Lausanne). 2018;9:375.
17. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;
44(235):291–303.
18. Raitakari OT, Juonala M, Kähönen M, Taittonen L, Laitinen T, Mäki-Torkko N, Järvisalo MJ, Uhari
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